Gatekeeping procedures in dose-response clinical trials based on the Dunnett test

被引:22
|
作者
Dmitrienko, Alex
Offen, Walt
Wang, Ouhong
Xia, Dan
机构
[1] Eli Lilly & Co, Lilly Corp Ctr, Lilly Res Labs, Indianapolis, IN 46285 USA
[2] Amgen Inc, Thousand Oaks, CA 91320 USA
[3] Wyeth Global Biostat, Collegeville, PA USA
关键词
multiple testing; gatekeeping tests;
D O I
10.1002/pst.190
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
This paper discusses multiple testing procedures in dose-response clinical trials with primary and secondary endpoints. A general gatekeeping framework for constructing multiple tests is proposed, which extends the Dunnett test [Journal of the American Statistical Association 1955; 50: 1096-1121] and Bonferroni-based gatekeeping tests developed by Dmitrienko et al. [Statistics in Medicine 2003; 22:2387-2400]. The proposed procedure accounts for the hierarchical structure Of the testing problem; for example, it restricts testing of secondary endpoints to the doses for which the primary endpoint is significant. The multiple testing approach is illustrated using a dose-response clinical trial in patients with diabetes. Monte-Carlo simulations. demonstrate that the proposed procedure provides a power advantage over the Bonferroni gatekeeping procedure. The power gain generally increases with increasing correlation among the endpoints, especially when all primary dose-control comparisons are significant. Copyright (C) 2006 John Wiley & Sons, Ltd.
引用
收藏
页码:19 / 28
页数:10
相关论文
共 50 条
  • [21] BIOLOGICAL BASES FOR CANCER DOSE-RESPONSE EXTRAPOLATION PROCEDURES
    WILSON, JD
    ENVIRONMENTAL HEALTH PERSPECTIVES, 1991, 90 : 293 - 296
  • [22] DOSE-RESPONSE RELATIONSHIPS FOR HUMAN-TUMORS - IMPLICATIONS FOR CLINICAL-TRIALS OF DOSE MODIFYING AGENTS
    WILLIAMS, MV
    DENEKAMP, J
    FOWLER, JF
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1984, 10 (09): : 1703 - 1707
  • [23] DOSE-RESPONSE RELATIONSHIP IN CLINICAL ONCOLOGY
    GEHAN, EA
    CANCER, 1984, 54 (06) : 1204 - 1207
  • [24] A flexible dose-response modeling framework based on continuous toxicity outcomes in phase I cancer clinical trials
    Lee, Se Yoon
    TRIALS, 2023, 24 (01)
  • [25] A flexible dose-response modeling framework based on continuous toxicity outcomes in phase I cancer clinical trials
    Se Yoon Lee
    Trials, 24
  • [26] Clinical dose-response effects of exercise
    Banister, EW
    Morton, RH
    FitzClarke, JR
    PHYSIOLOGY AND PATHOPHYSIOLOGY OF EXERCISE TOLERANCE, 1996, : 297 - 309
  • [27] Comparison of hierarchical EMAX and NDLM models in dose-response for early phase clinical trials
    Xiaqing Huang
    Byron J. Gajewski
    BMC Medical Research Methodology, 20
  • [28] The dose-response relationship in Phase I clinical trials and beyond: use, meaning, and assessment
    Emilien, G
    van Meurs, W
    Maloteaux, JM
    PHARMACOLOGY & THERAPEUTICS, 2000, 88 (01) : 33 - 58
  • [29] Guest editors' note for the special issue on "design and analysis of dose-response clinical trials"
    Ting, Naitee
    Grieve, Andy
    JOURNAL OF BIOPHARMACEUTICAL STATISTICS, 2006, 16 (05) : I - II
  • [30] Bayesian hierarchical EMAX model for dose-response in early phase efficacy clinical trials
    Gajewski, Byron J.
    Meinzer, Caitlyn
    Berry, Scott M.
    Rockswold, Gaylan L.
    Barsan, William G.
    Korley, Frederick K.
    Martin, Renee' H.
    STATISTICS IN MEDICINE, 2019, 38 (17) : 3123 - 3138